Indium (In-111) Chloride Curium

Indium-111, the active ingredient in Indium (In-111) Chloride Curium, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed for scintigraphic imaging of infection, inflammation, tumors and bone marrow in adult patients.

GNH USA supplies Indium (In-111) Chloride Curium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company emphasizes quality assurance, regulatory compliance and reliable cold‑chain logistics for radiopharmaceutical distribution across multiple continents and emerging markets.

Indium-111 chloride is used in diagnostic imaging to visualize specific disease processes.

Infection and inflammation imaging: provides scintigraphic visualization of infectious or inflammatory sites. Leukocyte labeling for abscess detection: labels patient white blood cells to locate abscesses and focal infections. Tumor imaging: highlights malignant lesions to assist in cancer staging and treatment planning. Bone marrow imaging: delineates marrow activity for assessment of hematologic disorders.

Adverse reactions to Indium-111 chloride are generally related to the injection procedure and radiation exposure.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Transient flushing: brief feeling of warmth or redness. - Nausea: mild upset stomach occurring shortly after administration. - Headache: temporary headache not requiring treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Radiation‑induced tissue injury: localized damage to organs receiving high dose. - Hematologic toxicity: significant reduction in blood cell counts.

When handling Indium-111 chloride, observe the following precautions. - Radiation safety: follow institutional protocols to limit exposure to staff and patients. - Pregnancy: avoid use unless benefits outweigh potential fetal radiation risk. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal function: assess kidney function as excretion is primarily renal. - Allergic history: screen for prior hypersensitivity to radiopharmaceuticals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions with Indium-111 chloride should be considered.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may result in cumulative radiation dose. - High‑dose chemotherapy: can increase bone marrow toxicity when combined. - Immunosuppressive agents: may alter leukocyte labeling efficiency.

Moderate Interactions (Monitor Closely): - Iodinated contrast agents: can affect image quality and biodistribution. - Beta‑blockers: may influence hemodynamic response to injection. - Steroids: may modify inflammatory uptake patterns.